Plexera Bioscience to Showcase Kx(TM) Array Technology
Lumera zu myNews hinzufügen Was ist das?
Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation
(NASDAQ:LMRA), announced today that it will present the latest
developments of its commercially branded Kx™
array technology at the upcoming PepTalk 2008 meeting on January 7-9 in
San Diego. Plexera’s Director of Application
Development, Dr. Michael Cicirelli, will present a poster entitled "Accelerating
Proteomics Discovery with Kx™ Array
Technology.”
Going significantly beyond the capabilities of current protein array
technologies, Kx™ array technology not
only tells researchers what is binding, but also how well, how much, and
how long the binding occurs. This dynamic information is critical in
identifying characteristics of potential drug candidates.
The Plexera™ KX5
System (formerly known as the ProteomicProcessor™
Instrument) is based on Kx™ array
technology and is a fully integrated, easy to use platform for analyzing
up to 5000 biomolecular interactions in a single run. The System offers
optimized printing of proteins on specialized surface chemistries,
automated array processing, dedicated reagents, and proprietary data
analysis software.
"Implementing the commercial branding
strategy of our Kx5 System marks the
achievement of an important strategic milestone,”
said Plexera’s Chief Executive Office, Dr.
Joseph Vallner. "We are now beginning to
build a strong presence for the Plexera™
brand by clearly articulating our core technical value proposition to
prospective buyers of the technology.”
Initially, the Plexera™ KX5
System will target antibody and biomarker discovery applications when it
commercially launches in May 2008. Plexera Bioscience is currently
engaging select customers to participate in an Early Access Program
using the Kx platform.
About Plexera Biosciences LLC
Plexera Biosciences LLC., a wholly owned subsidiary of Lumera
Corporation (NASDAQ:LMRA), develops and manufactures advanced analytical
tools and methods that enable life science researchers to probe the
human proteome for improved diagnostics, therapeutics, and knowledge of
the human condition. For more information, please visit www.plexera.com.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors
that could cause actual results to differ materially from those
projected in the company's forward-looking statements include the
following: market acceptance of our technologies and products; our
ability to obtain financing; our financial and technical resources
relative to those of our competitors; our ability to keep up with rapid
technological change; government regulation of our technologies; our
ability to enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from time
to time in the company's SEC reports, including its Annual Report on
Form 10-K, and its Quarterly Reports on Form 10-Q.
